Living Cell Technologies Ltd. (AU:1AI) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Algorae Pharmaceuticals has expanded its therapeutic pipeline with 24 new AI-generated drug targets for preclinical evaluation, focusing on oncology indications with unmet needs. This development, facilitated by their proprietary AlgoraeOS platform, underscores the company’s competitive edge in AI-driven drug discovery. Successful preclinical outcomes may lead to further development, potentially in collaboration with other pharmaceutical firms.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.
